Diagnosis and treatment of chronic cerebrovascular disease, use of pentoxifylline
https://doi.org/10.14412/2074-2711-2016-3-4-9
Abstract
Chronic cerebrovascular disease (CCVD) is one of the most common iagnoses in Russian neurology, by which is meant vascular cognitive impairment (VCI) in modern foreign literature. There are data available in the literature on the diagnosis and treatment of CCVD (VCI). Theresults of the author’s studies show that CCVD often masks other diseases (anxiety and depressive disorders, primary headache, peripheral vestibulopathy, and Alzheimer's disease) that are unfortunately poorly diagnosed in our country, so patients do not receive effective treatment. To modify risk factors for stroke (smoking and alcohol cessation, sufficient exercise), to normalize blood pressure (the use of antihypertensivemedications), to reduce blood cholesterol levels (statins), to perform antithrombotic therapy (antiplatelet agents and anticoagulants), and to use cognitive enhancers are of key importance when treating patients with CCVD (VCI). There are data on the use of pentoxifylline in patients with CCVD, vascular dementia.
About the Author
V. A. Parfenov
Department of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 11, Rossolimo St., Moscow 119021
Russian Federation
Russian Federation
References
1. Дамулин ИВ, Парфенов ВА, Скоромец АА, Яхно НН. Нарушения кровообращения в головном и спинном мозге. В кн.: Яхно НН, редактор. Болезни нервной системы. Руководство для врачей. Т.1. Москва: Медицина; 2005. С. 231-302. [Damulin IV, Parfenov VA, Skoromets AA, Yakhno NN. Circulatory disorders in the brain and spinal cord. In: Yakhno NN, editor. Bolezni nervnoi sistemy. Rukovodstvo dlya vrachei [Diseases of the nervous system. A guide for physicians]. Vol.1. Moscow: Meditsina; 2005. P. 231-302.]
2. Междунаpодная статистическая класcификация болезней и пpоблем, связанных со здоpовьем. Десятый пеpесмотp. (МКБ-10). Женева; 1995. [International statistical classification of diseases and problems related to health. Tenth revision. (IDC-10). Geneva; 1995.]
3. Harwart D. The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline ('Trental' 400). Curr Med Res Opin. 1979;6(2):73-84.
4. Blume J, RiIhlmann KU, de la Haye R, et al. Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline. J Med. 1992;23(6):417-32.
5. Шмидт ЕВ. Классификация сосудистых поражений головного и спинного мозга. Журнал невропатологии и психиатрии им. С.С. Корсакова. 1985;(9):1281-8. [Shmidt EV. Classification of vascular lesions of the brain and spinal cord. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 1985;(9):1281-8. (In Russ.)].
6. O'Brien J, Ames D, Gustafson L, et al, editors.Cerebrovascular disease, cognitive impairment and dementia. 2nd edition. Martin Dunitz; 2004.
7. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.
8. Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics. 2011 Jul; 8(3):361-73. doi: 10.1007/s13311- 011-0047-z.
9. Неверовский ДВ, Случевская СФ, Парфенов ВА. Дифференциальный диагноз дисциркуляторной энцефалопатии в амбулаторной практике. Неврология, нейропсихиатрия психосоматика. 2013;5(2):38-42. [Neverovskii DV, Sluchevskaya SF, Parfenov VA. Differential diagnosis of dyscirculatory encephalopathy in outpatient practice. Nevrologiya, neiropsikhiatriya psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):38-42. (In Russ.)]. doi: 10.14412/2074-2711-2013-2411
10. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.
11. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014 Jul;45(7):2160-236. doi: 10.1161/STR.0000000000000024. Epub 2014 May 1.
12. Baskys A, Hou AC. Vascular dementia: Pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.
13. Frampton JE, Brogden RN. Pentoxifylline (Oxpentifylline) A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging. 1995 Dec;7(6):480-503.
14. McCarty MF, O'Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 2016 Feb 8;3(1): e000365. doi: 10.1136/openhrt-2015- 000365. eCollection 2016.
15. Hohenberger P, Latz E, Kettelhack C, et al. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-a and melphalan. Ann Surg Oncol. 2003 Jun;10(5):562-8.
16. Okazaki S, Sakaguchi M, Miwa K, et al. Association of Interleukin-6 with the progression carotid atherosclerosis (a 9-year follow-up study). Stroke. 2014 Oct;45(10):2924-9. doi: 10.1161/STROKEAHA.114.005991. Epub 2014 Aug 19.
17. Bath PM, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;(3):CD000162.
18. Lauch ES, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the AHA/ASA. Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR.0b013e318284056a. Epub 2013 Jan 31.
19. Широков ЕА. Второе пришествие пентоксифиллина в превентивную кардионеврологию. Русский медицинский журнал. 2013;(5):1-3. [Shirokov EA. The second coming of pentoxifylline in prevention cardioneurology. Russkii meditsinskii zhurnal. 2013;(5):1-3. (In Russ.)].
20. Ott E, Fazekas F, Valetitsch H, et al. The rationale of rheological pharmacological therapy. Clinical Hemorheology. 1986;(6):35-40.
21. Herskovits E, Famulari A, Tamaroff L, et al. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol. 1985;24(1):73-81.
22. Black RS, Barclay LL, Nolan KA, et al. Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc. 1992 Mar;40(3):237-44.
23. The European Pentoxifylline Multi-infarct Dementia (EPMID) Study Group. European pentoxifylline multi-infarct dementia study. Eur Neurol. 1996;36(5):315-21.
24. Sha M, Callahan C. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord. 2003 Jan-Mar;17(1):46-54.
Review
For citations:
Parfenov V.A. Diagnosis and treatment of chronic cerebrovascular disease, use of pentoxifylline. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(3):4-9. https://doi.org/10.14412/2074-2711-2016-3-4-9
Views: 1047
Email this article 